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ABSTRACT FGD1 encodes a guanine nucle-
otide exchange factor (GEF) that specifically ac-
tivates the Rho GTPase Cdc42; FGD1 mutations
result in Faciogenital Dysplasia (FGDY, Aarskog
syndrome), an X-linked developmental disorder
that adversely affects the formation of multiple
skeletal structures. To further define the role of
FGD1 in skeletal development, we examined its
expression in developing mouse embryos and
correlated this pattern with FGDY skeletal de-
fects. In this study, we show that Fgd1, the mouse
FGD1 ortholog, is initially expressed during the
onset of ossification during embryogenesis. Fgd1
is expressed in regions of active bone formation
in the trabeculae and diaphyseal cortices of de-
veloping long bones. The onset of Fgd1 expres-
sion correlates with the expression of bone sialo-
protein, a protein specifically expressed in
osteoblasts at the onset of matrix mineralization;
an analysis of serial sections shows that Fgd1 is
expressed in tissues containing calcified and
mineralized extracellular matrix. Fgd1 protein is
specifically expressed in cultured osteoblast and
osteoblast-like cells including MC3T3-E1 cells
and human osteosarcoma cells but not in other
mesodermal cells; immunohistochemical studies
confirm the presence of Fgd1 protein in mouse
calvarial cells. Postnatally, Fgd1 is expressed
more broadly in skeletal tissue with expression
in the perichondrium, resting chondrocytes, and
joint capsule fibroblasts. The data indicate that
Fgd1 is expressed in a variety of regions of incip-
ient and active endochondral and intramembra-
nous ossification including the craniofacial
bones, vertebrae, ribs, long bones and phalanges.
The observed pattern of Fgd1 expression corre-
lates with FGDY skeletal manifestations and pro-
vides an embryologic basis for the prevalence of
observed skeletal defects. The observation that
the induction of Fgd1 expression coincides with
the initiation of ossification strongly suggests
that FGD1 signaling plays a role in ossification
and bone formation; it also suggests that FGD1
signaling does not play a role in the earlier
phases of skeletogenesis. With the observation
that FGD1 mutations result in the skeletal dys-
plasia FGDY, accumulated data indicate that
FGD1 signaling plays a critical role in ossifica-
tion and skeletal development. © 2000 Wiley-Liss, Inc.
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INTRODUCTION
FGD1 is implicated as an important participant in
skeletal formation because mutations in this gene re-
sult in the disease Faciogenital Dysplasia (FGDY), or
Aarskog syndrome (Pasteris et al., 1994; Gorski, 1998),
an X-linked skeletal dysplasia that adversely affects a
particular set of characteristic skeletal structures
(OMIM 305400). Most FGD1 mutations in FGDY pa-
tients are predicted to function as null alleles; thus the
X-linked recessive phenotype appears to be due to the
absence of the gene product in affected males (Pasteris
et al., 1994). Although minor urogenital anomalies are
associated with FGDY, FGD1 mutations appear to af-
fect the developing skeleton most severely and skeletal
abnormalities dominate the clinical manifestations of
the disease (Gorlin et al., 1990; Gorski, 1998). Clinical
findings typically include a unique pattern of develop-
mental skeletal abnormalities including disproportion-
ate acromelic short stature, widely spaced eyes (hyper-
telorism), maxillary and mandibular hypoplasia,
hypoplastic phalanges, and delayed bone maturation.
A variety of other skeletal malformations are also ob-
served including cervical spine abnormalities such as
spina bifida occulta, odontoid hypoplasia, fused cervical
vertebrae, segmentation anomalies and additional
pairs of ribs, and abnormally formed teeth (Gorlin et
al., 1990; Porteous and Goudie, 1991). The combined
clinical data indicate that FGD1 mutations adversely
affect a variety of skeletal elements including the
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craniofacial bones, vertebrae, ribs, long bones and pha-
langes, skeletal components derived from neural crest,
periaxial mesoderm, and lateral mesoderm, and com-
ponents formed by both endochondral and intramem-
branous ossification.
Microinjection and biochemical studies show that
FGD1 encodes a guanine nucleotide exchange factor
(GEF) that specifically activates the p21 GTPase
Cdc42, a member of the Rho (Ras homology) family of
GTPase proteins (Olson et al., 1996; Zheng et al., 1996).
FGD1 is one of about 25 different mammalian Rho
guanine nucleotide exchange factors (RhoGEFs). How-
ever, unlike most of the RhoGEFs that were identified
by transformation assay, presently, FGD1 is the only
disease-specific RhoGEF in which mutations result in
an inherited human developmental syndrome (Cerione
and Zheng, 1996; Whitehead et al., 1997). RhoGEFs
activate Rho GTPases by catalyzing the exchange of
bound GDP for GTP (Cerione and Zheng, 1996). Rho-
GEFs, and the Rho proteins they regulate, are typically
expressed throughout development in a wide range of
tissues (Cerione and Zheng, 1996; Whitehead et al.,
1997); however, the specific role that each RhoGEF
plays during mammalian development remains to be
determined. Rho GTPases regulate diverse cellular
processes including the organization of the actin cy-
toskeleton, cellular polarity, vesicular transport, cell
cycle progression, and the modulation of gene expres-
sion (Van Aelst and D’Souza-Schorey, 1997). By regu-
lating these cellular components and processes, Rho
proteins (and their RhoGEF activators) regulate cell
shape, motility, and differentiation, properties critical
to tissue morphogenesis (Hall, 1998). Biochemical
studies show that FGD1 is a specific Cdc42 activator
(Olson et al., 1996; Zheng et al., 1996). By activating
Cdc42, FGD1 stimulates fibroblasts to form filopodia,
cytoskeletal elements involved in cellular signaling
and adhesion (Olson et al., 1996). Through Cdc42,
FGD1 also activates the c-Jun N-terminal kinase sig-
naling cascade, a pathway that regulates cell growth
and differentiation. Amassed data indicate that FGD1
is an activating component of the Cdc42 intracellular
signaling pathway.
To gain further understanding of the function of
FGD1 in skeletal formation, we studied the expression
of Fgd1, the FGD1 mouse ortholog (Pasteris et al.,
1995), in the developing mouse embryo. Here we dem-
onstrate that Fgd1 has a unique pattern of expression;
transcripts are most abundant in the ossifying skeletal
components of craniofacial bones, vertebrae, ribs, long
bones and phalanges, skeletal components derived
from neural crest, periaxial mesoderm, and lateral me-
soderm. Immunoblot studies show that the Fgd1 pro-
tein is expressed in mouse calvarial osteoblasts, the
osteoblast-like cell line MC3T3-E1, and human osteo-
sarcoma cell lines. These results show that Fgd1 has a
restricted spatiotemporal pattern of expression and
that its expression is limited to regions of incipient and
active ossification including the craniofacial bones. The
observation that the induction of Fgd1 expression co-
incides with the initiation of ossification strongly sug-
gests that FGD1 signaling plays a role in ossification
but not in the earlier phases of skeletogenesis. Further-
more, these results show that the pattern of Fgd1 ex-
pression directly corresponds to the abnormalities of
endochondral and intramembranous bone formation
observed in Faciogenital Dysplasia. Accumulated data
strongly suggests that FGD1 signaling plays a critical
role in skeletal formation.
RESULTS
RNA In Situ Hybridization Analysis of Fgd1
Expression
Northern blot and non-quantitative RT-PCR studies
were previously used to examine the pattern of FGD1
expression in a limited number of adult and embryonic
human tissues (Pasteris et al., 1994, 1995); however,
skeletal tissues were not included in these studies.
Preliminary northern blot analyses showed that Fgd1
transcripts were predominantly expressed in mouse
skeletal tissue (Pasteris et al., 1995; data not shown).
Thus, to further elucidate the role of FGD1 in skeletal
formation, additional studies were performed to deter-
mine a more precise spatiotemporal pattern of Fgd1
expression during mouse embryogenesis.
Consistent with prior northern blot studies, in situ
hybridization studies show that Fgd1 expression is pre-
dominantly expressed in developing skeletal tissue in
the mouse embryo. The earliest evidence of Fgd1 ex-
pression is first detected in the base of the skull and
cervical vertebrae in E14.5–E15.5 embryos (Fig. 1). In
these embryos, Fgd1 transcripts are detected in the
cartilage primordia of the neural arches of the cervical
vertebrae and the cartilage primordia of the basioccip-
ital bone. These skeletal components are known to
contain the earliest centers of ossification; these ossifi-
cation centers typically begin to form at about E14–
E14.5 (Kaufman, 1992). An analysis of adjacent tissue
sections shows that, in the neural arches of the E14.5
cervical vertebrae and the cartilage primordia of the
E15.5 basioccipital bone, the distribution of detected
Fgd1 transcripts directly corresponds to regions of cal-
cified tissue detected by alizarin S red stain within
these skeletal elements (Fig. 1). Anti-bone sialoprotein
antibodies were used to perform immunocytochemical
studies on adjacent tissue sections to confirm these
observations. In contrast to other bone matrix proteins,
bone sialoprotein (BSP) has a very restricted tissue
distribution and is almost exclusively expressed by os-
teoblasts at the onset of matrix mineralization (Bianco
et al., 1991; Robey, 1996). An analysis of adjacent tis-
sue sections shows that Fgd1 expression directly cor-
responds to regions of BSP protein expression in em-
bryonic neural arch and basioccipital tissue (Fig. 1),
tissues that are initiating early ossification.
Beginning at E15.5–E16.5, Fgd1 is expressed in the
midshaft cortex and developing trabeculae of the de-
veloping long bones (Fig. 2). In older mouse embryos
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(E18.5) and newborn mouse pups (P1), Fgd1is ex-
pressed in the diaphysis of the long bones and within
trabecular bone, regions of active bone formation. Se-
rial tissue sections were analyzed with alizarin S red
and Von Kossa stain to identify calcified and mineral-
ized tissues, respectively. These studies showed that
Fgd1 expression corresponds to regions of calcified and
mineralized cortical and trabecular bone tissue (Fig. 2).
In these embryos and pups, Fgd1 expression is limited
to tissues undergoing bone formation; Fgd1 expression
is not detected in non-skeletal tissue, nor is Fgd1 ex-
pressed in non-ossified skeletal tissue such as prolifer-
ating and hypertrophied chondrocytes (Fig. 2). Fgd1
expression is also observed in other skeletal elements
undergoing ossification, including the ribs and the dis-
tal and proximal long bones of the upper and lower
extremities (data not shown). In some tissue sections,
silver grains were deposited above cornified epithelia
(i.e., Figs. 2 and 3); however, control hybridizations,
including the use of sense Fgd1 probe, showed that
these signals were non-specific and artifactual (data
not shown). With the results of the embryonic skull
base and cervical vertebrae expression studies, the
data show that Fgd1 is predominantly expressed in
regions of active embryonic ossification.
An analysis of multiple E10.5–E14.5 embryos failed
to identify Fgd1 transcripts before E14.5 (data not
shown). Specifically, Fgd1 transcripts were not de-
tected in skeletal condensations prior to E14.5, before
the onset of ossification. In addition, an analysis of
multiple E10.5–E14.5 embryos also failed to detect
Fgd1 transcripts in non-skeletal tissue. In particular,
no evidence of Fgd1 expression was found in the devel-
oping urogenital structures including the developing
genital tubercle, a structure formed during this period
of embryogenesis (Kaufman, 1992). It has been postu-
lated that the genital tubercle may be involved in the
development of FGDY urogenital anomalies (Gorlin et
al., 1990). The observation that the initiation of Fgd1
expression coincides with the onset of ossification
strongly suggests that Fgd1 signaling plays a role in
ossification and bone formation. This observation also
suggests that Fgd1 does not play a prominent role in
the earlier phases of skeletogenesis.
Additional in situ hybridization studies were per-
formed to determine the pattern of Fgd1 expression in
embryonic craniofacial bones. Coronal, transverse, and
sagittal sections of E18.5 embryos showed that Fgd1
was expressed in the cortex and trabeculae of the de-
veloping maxilla and mandible, the hard palate, and
the inferomedial part of nasal septum (Figs. 3 and 4).
These studies showed that Fgd1 was expressed in all of
the craniofacial skeletal components containing ossifi-
cation centers including the frontal, parietal, temporal,
and exoccipital bones (data not shown). Fgd1 was also
expressed in craniofacial cartilage primordia prior to
evident ossification center formation (i.e., Fgd1 expres-
sion in the cartilage primordia of the nasal turbinate;
Fig. 4E and F). In contrast, Fgd1 expression was nota-
bly absent in Meckel’s cartilage (Fig. 3). Detectable
Fgd1 expression was also absent in the cartilage of the
ear, thyroid, and trachea (data not shown), cartilagi-
nous components that normally do not ossify. Fgd1
expression was also detected in tissues surrounding
the primordia of the upper and lower incisor teeth
(Figs. 3B and 4D); however, it was not possible to
unequivocally identify the expressing cells. Thus, to-
gether with the results showing the pattern of Fgd1
expression in embryonic long bones and cervical verte-
brae, the amassed data indicate that Fgd1 is expressed
in regions of incipient and/or active endochondral and
intramembranous ossification in the mouse embryo
during skeletal formation.
Immunoblot and Immunocytochemical Analysis
of Fgd1 Expression
Immunoblot analyses were performed to confirm
that Fgd1 protein was expressed in primary mouse
skeletal and osteoblast-like cells (Fig. 5A). When the
myc epitope-tagged Fgd1 expression construct, pTGE-
myc-Fgd1, was expressed in HEK 293 cells, anti-Fgd1
antibodies detected a single protein migrating at 149
kDa. The myc-epitope monoclonal antibody (9E10) de-
tected an identically sized protein; similar results were
obtained when pTGE-myc-Fgd1 was expressed in
COS1 cells (data not shown). No Fgd1 antigen was
detected in non-transfected cells. As shown in Figure
5A, the anti-Fgd1 antibody detected a protein migrat-
ing at 107 kDa in isolated primary mouse calvarial
cells (PMC cells), a standard preparation for osteoblast
cells (Majeska, 1996). The 107 kDa size of the detected
protein coincided with the predicted size of the Fgd1
protein (Pasteris et al., 1995). Anti-Fgd1 antibody de-
tected an identically sized 107 kDa protein in
MC3T3-E1 cells, a permanent non-transformed osteo-
blast-like cell line derived from normal mouse bone
that retains the ability to form well-developed bone
matrix in culture (Sudo et al., 1983). In contrast, Fgd1
antigen was not detected in C3H10T1/2 and NIH 3T3,
two independently derived permanent mouse embry-
onic fibroblast cell lines. Similarly, no Fgd1 antigen
was detected in the non-skeletal tissues from juvenile
mice including brain, skin, eye, lung, and spleen (data
not shown). Fgd1 antigen was detected in two different
human osteosarcoma cell lines, MG63 and SaOS2 (Fig.
5A). In addition to the detected 107-kDa protein, MG63
and SaOS2 homogenates contained additional cross-
reacting proteins; these consisted of an apparent 107
kDa doublet in SaOS2 cells, and 149 and 83 kDa pro-
teins in MG63 and SaOS2 cells, respectively. The 149
kDa protein detected in the MG63 cells coincided with
the recombinant Fgd1 protein expressed in transfected
HEK 293 and COS1 cells (Fig. 5A). These results show
that Fgd1 protein is expressed in primary mouse cal-
varial cells and several different types of clonal osteo-
blast-like cells. Although we cannot exclude the possi-
bility that the anti-Fgd1 antibodies may detect non-
Fgd1 cross-reacting proteins, the data suggest that, in
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Fig. 1. Fgd1 expression in the base of the skull and cervical verte-
brae. Serial sagittal sections of the head and neck of E14.5 and E15.5
mouse embryos were used for in situ hybridization. Successive sections
were used to visualize the spatiotemporal pattern of Fgd1 expression
(dark field, DF) compared to the morphology of adjacent tissue sections
stained with hematoxylin and eosin (HE), alizarin S red (AR), and immu-
nohistochemical staining with bone sialoprotein antibody (BSP): B, car-
tilage primordium of the basioccipital bone (clivus); C, cartilage primor-
dium of the body and neural arch of a cervical vertebra (C1, the first
vertebra; C2, the second vertebra, etc.); E, epiglottis; OR, oropharynx.
Precipitated silver grains indicative of detected Fgd1 transcript appear
white against black under dark field illumination. Calcified tissue stains
reddish brown with alizarin red and bound BSP antibody and attached
DAB/metal reagent stain black. Photomicrographs showing BSP immu-
nohistochemical staining are shown at higher magnification.
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Fig. 2. Expression of Fgd1 in the cortex and trabeculae of developing
long bones. A: Morphology of a growth plate and diaphysis of a tibia at
high-power magnification. Longitudinal sections of a tibia from an E18.5
mouse embryo were stained with hematoxylin and eosin (A) to visualize
the morphology of the growth plate and the bony trabeculae of the
diaphysis and alizarin red (B) to differentiate between cartilage (dark
blue) and bone (reddish brown): P, proliferating chondrocytes; H, hyper-
trophic chondrocytes; B, bony trabeculae and bone marrow. B: Fgd1
expression in mouse long bones. Serial longitudinal sections of the long
bones of E16.5 and E18.5 mouse embryos and 1-day-old mouse pups
(P1) were used for isotopic in situ hybridization; longitudinal sections of
the radius and ulna (E16.5) and the tibia (E18.5 and P1) are shown.
Serial sections were used to visualize the spatiotemporal pattern of Fgd1
expression (dark field, DF) compared to the morphology of adjacent
tissue sections stained with hematoxylin and eosin (HE), alizarin red
(AR), and Von Kossa stain (VK); R, radius; U, ulna; T, tibia; F, femur.
Mineralized tissue stains black with Von Kossa reagent.
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Fig. 3. Fgd1 expression in embryonic craniofacial bones (part 1).
Coronal sections of the head of an E18.5 mouse embryo were used for in
situ hybridization. Serial sections stained with hematoxylin and eosin
(HE) show the anterior (A) and mid-segment parts of the mandible and
maxilla (C). Dark field sections immediately adjacent to the HE sections
show the pattern of Fgd1 expression in these tissues (B,D); LI, primor-
dium of the lower incisor; MC, Meckel’s cartilage; Mn, mandible; Mx,
maxilla; NS, ossification in inferomedial part of nasal septum; T, tongue;
UI, primordium of the upper incisor.
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Fig. 4. Fgd1 expression in embryonic craniofacial bones (part 2).
Transverse (A–D) and sagittal (E,F) sections of the head of an E18.5
mouse embryo were used for in situ hybridization. Serial sections stained
with hematoxylin and eosin (HE) show two transverse sections through
the palate (A) and mandible (C), respectively, and a sagittal section
through the anterior part of the head (E). Dark field sections immediately
adjacent to the HE sections show the spatiotemporal pattern of Fgd1
expression in these tissues (B, D, and F); LI, lower incisor primordium;
Mn, mandible; Mx, maxilla; NC, nasal cavity; NT, cartilage primordium of
the nasal turbinate; P, palate shelf; T, tongue; UI, upper incisor primor-
dium.
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some cells, Fgd1 protein may be post-translationally
modified. Previous studies identified several potential
N-linked glycosylation sites in the predicted Fgd1 se-
quence (Pasteris et al., 1994); the specific nature of
Fgd1 post-translational modification remains to be de-
termined.
Immunohistochemical staining was performed
with anti-Fgd1 antibodies to confirm the expression
Fig. 5. Fgd1 protein is expressed in primary mouse calvarial and
osteoblast-like cells. A: Cellular homogenates were studied by immuno-
blot analysis to identify cells expressing Fgd1 protein. Homogenates
were obtained from human embryonic kidney 293 cells (lane 2; 200 mg
protein), 293 cells transfected with the Fgd1 expression construct pTGE-
myc-Fgd1 (lane 1; 10 mg protein), primary mouse calvarial cells (PMC
cells) (lane 3; 50 mg protein), mouse osteoblast-like MC3T3-E1 cells
(lane 4; 100 mg protein), permanent mouse fibroblast cells C3H10T1/2
(lane 5; 200 mg protein) and NIH3T3 (lane 6; 200 mg protein), and human
osteosarcoma cells MG63 (lane 7; 200 mg protein) and SaOS2 (lane 8;
100 mg protein). The epitope-tagged recombinant Fgd1 protein migrates
at an estimated 149 kDa. A protein migrating at 107 kDa (arrow), the
predicted size of the Fgd1 protein, is detected by the anti-Fgd1 antibody.
B: Immunohistochemical analysis of Fgd1 protein expression in PMC
cells. PMC cells stain with the anti-Fgd1 antibody (A, low-power magni-
fication; B, high-power magnification). No background staining is de-
tected in PMC cells stained with rabbit pre-immune serum (C). PMC cells
stain with anti-bone sialoprotein (BSP) antibody (D).
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of Fgd1 protein expression in PMC cells (Fig. 5B).
When studying PMC cell fractions most competent in
forming mineralized bone tissue as assayed by cul-
tured bone nodule formation (see Cell Lines and Pri-
mary Mouse Cells; fractions 3 and 4), .90% of the
cells examined stained with anti-Fgd1 antibody. A
similar proportion of cells stained with the anti-BSP
antibody. In contrast, no background staining was
detected with pre-immune sera (Fig. 5B). These stud-
ies show that Fgd1 protein is expressed in primary
osteoblasts and clonal pre-osteoblast cell lines, data
consistent with the RNA in situ hybridization stud-
ies. Although we can not exclude the possibility that
Fgd1 protein may be expressed in additional cells
during skeletogenesis, together these results indi-
cate that Fgd1 is expressed in osteoblasts and pre-
osteoblasts during endochondral and intramembra-
nous bone formation in the mouse embryo.
Fgd1 Expression in the Skeletal Components of
2-Week-Old Mouse Pups
Additional in situ hybridization studies were per-
formed to determine the pattern of Fgd1 expression in
juvenile 2-week-old mice. These studies showed that,
as in the mouse embryo, Fgd1 had a limited pattern of
expression and that its expression was essentially con-
fined to skeletal tissue. However, in contrast to the
pattern of Fgd1 expression in embryos and newborn
mouse pups, in 2-week-old mice, Fgd1 was predomi-
nantly expressed in the perichondrium, resting chon-
drocytes, and joint capsule fibroblasts within the joints
of the upper and lower extremities (Fig. 6). This pat-
tern of expression was observed in both the proximal
(knee) and distal (interphalangeal) joints. Although a
small amount of Fgd1 expression was detected in the
bony trabeculae of the long bones, Fgd1 expression
Fig. 6. Fgd1 expression in the skeletal tissues of a juvenile mouse.
Serial longitudinal sections of the long bones of a 14-day-old juvenile
mouse were used for in situ hybridization. Sections stained with hema-
toxylin and eosin (HE) show the proximal tibia (A) and the proximal and
distal phalanges of the upper extremity (C). Dark field sections immedi-
ately adjacent to the HE sections show the spatiotemporal pattern of
Fgd1 expression in these tissues (B,D); DP, distal phalanx; F, femur; P,
patella; PP, proximal phalanx; T, tibia.
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were predominantly limited to the perichondrium,
resting chondrocytes, and joint capsule fibroblasts.
Fgd1 expression was not detected in non-skeletal tis-
sue. These results indicate that, while Fgd1 expression
may be limited to osteoblasts and pre-osteoblasts dur-
ing mouse embryogenesis, postnatally, Fgd1 exhibits a
broader pattern of expression. Therefore, in addition to
the role it plays in osteoblast biology, Fgd1 may play a
broader role in mammalian skeletogenesis.
Skeletal Abnormalities Observed in
Faciogenital Dysplasia
To provide a correlation between the spatiotemporal
pattern of Fgd1 expression and skeletal anomalies, we
reviewed the spectrum of skeletal abnormalities re-
ported in the literature and evaluated by us in more
than 110 patients with Faciogenital Dysplasia (Gorlin
et al., 1990; Porteous and Goudie, 1991). All patients
had multiple skeletal abnormalities; the frequency of
each of the skeletal abnormalities was tabulated and
summarized in Table 1. As previously recognized,
craniofacial anomalies (hypertelorism, maxillary hyp-
oplasia, and a broad nasal bridge), short stature, and
anomalies of the distal extremities (brachydactyly and
hypoplastic phalanges) were prevalent among FGDY
patients. While not tabulated in the literature, delays
in the appearance of ossification centers and cervical
spine anomalies were commonly observed among our
series of patients. The skeletal components adversely
affected by the FGDY phenotype are diverse and in-
clude the craniofacial bones, vertebrae, ribs, long bones
and phalanges, skeletal components derived from neu-
ral crest, periaxial mesoderm, and lateral mesoderm
and components formed by both endochondral and in-
tramembranous ossification. These skeletal abnormal-
ities coincide with regions that predominantly express
murine Fgd1.
DISCUSSION
In this study, we demonstrate that Fgd1 is expressed
in a unique and limited spatiotemporal pattern that is
restricted to developing skeletal elements. Fgd1 is ini-
tially expressed during embryogenesis within the car-
tilage primordia of the cervical vertebrae and basioc-
cipital bone and this expression coincides with the
onset of ossification. Later in embryogenesis, Fgd1 is
expressed in regions of active bone formation in the
trabeculae and diaphyseal cortices of developing long
bones. Fgd1 is also expressed in the cartilage primor-
dia and ossified components of embryonic craniofacial
bones. Immunoblot analyses show that Fgd1 protein is
expressed in human osteosarcoma cells and cultured
osteoblast and osteoblast-like cells including primary
mouse calvarial and clonal MC3T3-E1 cells, cells that
form bone nodules in culture. Postnatally, Fgd1 is ex-
pressed more broadly in skeletal tissue with expression
in the perichondrium, resting chondrocytes, and joint
capsule fibroblasts. The data indicate that, during
mouse skeletogenesis, Fgd1 is expressed in a variety of
regions of incipient and/or active endochondral and
intramembranous ossification including the skull and
craniofacial bones, vertebrae, ribs, long bones and pha-
langes, skeletal components derived from neural crest,
periaxial mesoderm, and lateral mesoderm. The ob-
served pattern of Fgd1 expression correlates with the
skeletal manifestations resulting from human FGD1
mutations in Faciogenital Dysplasia. We conclude that
the characteristic skeletal abnormalities of FGDY are
the direct result of deficiencies in FGD1 signaling. The
data indicate a unique and critical role for FGD1 sig-
naling in osteoblast and skeletal development.
The data show that, during mouse embryogenesis,
the induction of Fgd1 expression coincides with the
initiation of ossification. These results strongly suggest
that Fgd1 signaling plays a role in ossification and
bone formation, a finding supported by the observation
that FGD1 mutations result in the skeletal dysplasia
FGDY. These results also suggest that Fgd1 signaling
does not play as significant a role in the earlier phases
of skeletogenesis. Skeletal formation is emerging as a
complex process that requires the regulated differenti-
ation of a variety of cell types. During embryogenesis,
skeletal formation is initiated by the aggregation of
undifferentiated mesenchymal cells into condensa-
TABLE 1. Skeletal Features in Faciogenital Dysplasia Patientsa
Skeletal abnormality Published cases Michigan series Total frequency (%)
Short stature (,3rd centile) 86/98 15/16 101/114 (89)
Delayed ossification centers NA 14/16 14/16 (88)
Hypertelorism 89/100 16/16 105/116 (91)
Maxillary hypoplasia 84/104 14/16 89/120 (74)
Broad nasal bridge 50/75 13/16 63/91 (69)
Cervical spine anomalies NA 9/16 9/16 (56)
Rib and sternal anomalies 34/74 5/16 39/90 (43)
Short/broad hands 63/77 15/16 78/93 (84)
Brachydactyly 63/77 14/16 77/93 (83)
Hypoplastic phalanges 37/45 10/16 47/61 (77)
Syndactyly 45/73 13/16 58/89 (65)
Joint laxity 46/64 12/16 58/80 (72)
aNA denotes that information is not available in the literature.
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tions; these cells subsequently differentiate to form
cartilaginous primordia (Eriebacher et al., 1995). Dur-
ing the process of endochondral ossification, portions of
the cartilaginous primordia cease proliferation, become
hypertrophic, and alter the extracellular matrix to al-
low vascularization and the replacement of cartilage
with bone. Thus, the observation that Fgd1 is predom-
inantly expressed during endochondral and intramem-
branous bone formation indicates that, unlike skeletal
dysplasia genes that act during the formation of skel-
etal condensations, such as short ear and brachypo-
dism (King et al., 1994; Storm et al., 1994), Fgd1 plays
a role in embryologic ossification.
Our data indicate that Fgd1 expression demon-
strates a strong correlation with structural and skele-
tal abnormalities comprising the Faciogenital Dyspla-
sia phenotype. The craniofacial abnormalities observed
in FGDY (maxillary hypoplasia and hypertelorism; Ta-
ble 1) correspond with the observed expression pattern
of Fgd1 in the developing skull bones of the mouse
embryo. The cervical vertebral, rib, and sternal abnor-
malities directly correspond to the expression of Fgd1
in the cartilaginous primordia of these developing skel-
etal elements. Fgd1 is predominantly expressed in the
trabeculae and diaphyseal cortices of developing long
bones of the appendicular skeleton; this expression pat-
tern corresponds to the acromelic shortening of the
long bones of FGDY patients and may, in part, explain
the short stature observed in FGDY. No evidence of
Fgd1 expression was found in the developing urogeni-
tal structures including the developing genital tuber-
cle, a structure that may be affected by the observed
FGDY urogenital anomalies (Gorlin et al., 1990). Thus,
our data do not provide additional insight into the
molecular basis for observed minor FGDY urogenital
anomalies. It is possible that our analysis was not
sufficiently sensitive to detect Fgd1 transcripts in
these tissues. Alternatively, the spatiotemporal pat-
tern of murine Fgd1 expression may differ from that
observed during human embryogenesis. The genera-
tion of an Fgd1-deficient mouse mutation will assist in
the further delineation of the molecular basis for the
mouse and human FGDY phenotype. In postnatal
mice, Fgd1 is also expressed in the perichondrium,
resting chondrocytes, and joint capsule fibroblasts of
the proximal and distal appendicular skeleton; this
expression pattern may have significance for the joint
anomalies (joint contractures and joint laxity) observed
in the majority of FGDY patients (Gorlin et al., 1990;
Porteous and Goudie, 1991). In addition, the RNA in
situ hybridization and immunoblot studies show that
Fgd1 expression coincides with incipient and active
ossification; this expression pattern corresponds to the
generalized delay of ossification observed in FGDY pa-
tients.
The combined data show that Fgd1 is expressed in
essentially all regions of active endochondral and in-
tramembranous ossification. However, although the
FGDY phenotype consists of some features that may cor-
respond to bone formation in general (i.e., delayed ossifi-
cation), FGD1 mutations typically affect the size and
shape of a limited number of characteristic skeletal ele-
ments and not others. There may be several reasons as to
why FGD1 mutations fail to yield a more uniform or
generalized pattern of skeletal abnormalities. Although
FGD1’s role in the activation of Cdc42 is established
(Olson et al., 1996; Zheng et al., 1996), in skeletal tissue,
FGD1 may be only one of several Cdc42 activators. Mul-
tiple mammalian RhoGEF proteins have been shown to
activate Cdc42, and several Cdc42GEFs are known to be
expressed in skeletal tissue (Whitehead et al., 1997).
Thus, the observed FGDY phenotype is likely to be the
result of only a partial deficiency in Cdc42 activation and,
in an affected FGDY individual, different skeletal ele-
ments may display varying degrees of deficiency. While
our studies demonstrate the pattern of Fgd1 expression,
this data does not provide a measure of Fgd1 protein
activity or Cdc42 signaling. Thus, the concentration of
activated Fgd1 protein and/or the significance of FGD1
signaling may vary among the skeletal elements. In S.
cerevisiae, S. pombe, D. melanogaster, and C. elegans, the
loss of RhoGEF activity is functionally equivalent to the
loss of the target Rho protein (Boguski and McCormick,
1993); thus, it is likely that a loss of FGD1 activity results
in disrupted Cdc42 signaling. Several observations indi-
cate that Cdc42 signaling and actin cytoskeletal regula-
tion may play a critical role in the molecular and cellular
biology of bone tissue. In embryonic chick osteoblasts, an
intact actin cytoskeleton is required for the regulated
expression of osteopontin in response to mechanical
strains (Toma et al., 1997). Studies show that the actin
cytoskeleton and the Rho signaling cascade are involved
in the detection and response to fluid shear induced me-
chanical signaling in MC3T3-E1 osteoblasts (Pavalko et
al., 1998). Additional studies have demonstrated that the
actin cytoskeleton is critical for determining and main-
taining osteocyte shape (Tanaka-Kamioka et al., 1998).
These observations suggest that FGD1/Cdc42 signaling
may play a role in the organization of the osteoblast actin
cytoskeleton or in sensing mechanical stress. Although
we cannot rule out the formal possibility the FGD1 may
be involved in additional signaling pathways, the accu-
mulated data strongly indicate that Faciogenital Dyspla-
sia is a disorder of FGD1/Cdc42 signaling in the develop-
ing skeleton.
EXPERIMENTAL PROCEDURES
RNA In Situ Hybridization
C57BL/6 mice were purchased from Jackson Labora-
tory and bred to obtain embryos and pups. Embryos
were removed at various ages and staged according to
Kaufman (1992); noon of the day of detection of a vag-
inal plug was considered embryonic day (E) 0.5. All
animal experiments were carried out under the ap-
proval of the University of Michigan Committee on Use
and Care of Animals. Tissues and embryos were posi-
tioned in OCT compound (Sakura, CA), rapidly frozen
in hexane with dry ice, and 10–12-mm serial sections
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were made using a Zeiss HM500 cryostat. Sections
were treated for hybridization as described (Simmons
et al., 1989) with modification. Sections were fixed in
4% paraformaldehyde-PBS for 1 hr at room tempera-
ture, incubated in 100 mM Tris-HCl (pH 8.0), 50 mM
EDTA, 1 mg/ml of proteinase K for 15 min at 37°C, and
incubated in 100 mM triethanolamine, pH 8.0, 0.25%
(v/v) acetic anhydride for 10 min at room temperature.
Following acetylation, sections were washed twice in
2 3 SSC, and dehydrated in graded alcohols. The
503-bp PstI/EcoRI fragment (nt 2577–3080) from the 3’
untranslated region of the mouse Fgd1 gene (Pasteris
et al., 1995) was used as template to generate
[35S]UTP-labeled sense and antisense riboprobes to a
specific activity of approximately 3 3 109 disints min-1
mg-1 RNA per the recommendations of the RNA poly-
merase supplier (Novagen, WI). In situ hybridization
was performed as described (Keegan et al., 1994) with
modifications. Sections were hybridized in 50% form-
amide, 0.6 M NaCl, 10 mM Tris-HCl (pH 7.5), 1 mM
EDTA, 50 mg/ml heparin, 10 mM DTT, 10% PEG-8000,
1 3 Denhardt’s solution, 0.5 mg/ml tRNA at a final
concentration of approximately 9 3 104 disints min-1
ml-1 in a humid chamber for 16–24 hr at 58°C. Follow-
ing post-hybridization washes, slides were coated with
NBT2 emulsion (diluted 1:1 with 0.3 M sodium acetate)
and exposed at 4°C for 5–14 days; exposure times were
guided by overnight exposures to Hyperfilm-MP (Am-
ersham, IL). Slides were developed in D19 developer
per supplier recommendations (Kodak, NY), and
counter stained with cresyl violet. Slides were viewed
with a Leitz Orthoplan microscope; images were digi-
tally captured using a Sony DKC5000 CCD camera and
were directly imported into Adobe PhotoShop 5.0.
Antibodies
Polyclonal anti-Fgd1 antibodies were produced by
immunizing New Zealand white rabbits with a multi-
ple antigen peptide (MAP) containing the synthetic
peptide GFEVGPPEAGERPDRRHVFKIT (Fgd1 resi-
dues 871–892) covalently linked to a polylysine core
peptide. Immune sera and polyclonal antibodies were
prepared by standard procedures (Harlow and Lane,
1999). Polyclonal antibodies were selected based on the
immunoreactivity of the immune sera in Western blots
studies using Fgd1 expression constructs in control
and transiently transfected cell lines and immunohis-
tochemical staining analyses. Dr. R. Franceschi (Uni-
versity of Michigan) generously provided the rabbit
anti-bone sialoprotein (BSP) antibody.
Histochemical Staining and
Immunocytochemistry
Frozen tissue sections were fixed in 4% formalin-PBS
for 30 min. Hematoxylin and eosin staining was per-
formed as described (Bancroft and Stevens, 1996). Von
Kossa staining was performed to identify mineralized
bone tissue as previously described (Long et al., 1990).
Alizarin S red staining was performed to identify cal-
cified tissues as described (Bancroft and Stevens,
1996); following alizarin staining, sections were coun-
terstained with methyl green as previously described
(Harlow and Lane, 1999). For immunohistochemical
staining, frozen tissue sections and cultured primary
mouse calvarial cells on coverslips were fixed in 10%
formalin for 30 min, rinsed in water, and incubated in
0.02% hydrogen peroxide for 30 min. Immunohisto-
chemical staining was performed with the Immuno-
Pure ABC peroxidase rabbit IgG staining reagents per
the producer’s recommendations (Pierce, IL) with mod-
ifications. Slides were rinsed in PBS, 0.1% Tween 20
for 20 min and incubated in blocking solution (1.5%
goat serum, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl,
0.01% Tween 20, 5% milk) for 1 hr. Slides were incu-
bated in antibodies (1:100 anti-BSP or 1:50 anti-Fgd1)
in blocking solution overnight at 4°C. Bound antibody
complexes were detected using the DAB/metal concen-
trate substrate per producer’s recommendations
(Pierce, IL). Slides were dehydrated with a series of
alcohol washes, dried, and coverslips were mounted
with Permount (Fisher).
Cell Lines and Primary Mouse Cells
The non-transformed osteoblast-like mouse cell line
MC3T3-E1 (Sudo et al., 1983) was obtained from Dr.
Franceschi. Cell lines derived from human osteosarco-
mas, MG-63 (Franceschi et al., 1985) and SaOS (Rodan
et al., 1987), were obtained from Dr. Long (University
of Michigan). Mouse embryonic fibroblast cell lines
C3H10T1/2 (clone 8) and NIH-3T3, transformed hu-
man embryonic kidney cell line HEK 293, and SV40
transformed green monkey cell line COS1 were ob-
tained from the American Type Culture Collection
(Rockville, MD). MC3T3-E1 cells were cultured in
a-modified minimum essential medium (a-MEM) and
MG-63 cells were cultured in RPMI 1640 medium; all
other cell lines were cultured in Dulbecco’s modified
Eagle Medium (DMEM). All media was supplemented
with 10% fetal calf serum (FCS). Primary mouse cal-
varial cells were isolated as previously reported (Mc-
Cauley et al., 1996) with modifications. Calvaria of
1–4-day-old mice were dissected, isolated from perios-
teum, and subjected to sequential digestions of 20, 40,
90, and 60 min in 2 mg/ml collagenase A (Boehringer-
Mannheim, IN) with 0.25% trypsin (Gibco BRL). Cells
from the third and fourth digest were washed, counted,
and plated in a-MEM supplemented with 10% FCS, 50
mg/ml ascorbic acid and 10 mM Na b-glycerol phos-
phate at a density of 55,000 cells/cm2. Primary cultures
were used without passage. Cultures were incubated in
a humidified incubator in 5% CO2 at 37°C.
Expression Constructs and Cell Transfections
The pTARGET vector (Promega, WI) was modified to
generate an expression vector containing a translation
initiation consensus sequence and myc-epitope tag. To
generate vector pTE, pTARGET DNA was digested
with EcoRI and ligated to annealed oligomers: 5’-AAT-




erate vector pTGE, pTE DNA was digested with EcoRI
and ligated to annealed oligomers: 5’-AATTTAGGATC-
CCGGGCTAGCCATATGCTCGAGACGCGTCGACG-3’
and 5’-AATTCGTCGACGCGTCTCGAGCATATGGCT-
AGCCCGGGATCCTA-3’. The pTGE-myc-Fgd1 expres-
sion construct was generated by cloning the Fgd1 BlpI/
EcoRI cDNA restriction fragment (residues 18–960;
Pasteris et al., 1995) into pTGE in frame. All constructs
were verified by DNA sequencing. COS1 and HEK 293
cells were transiently transfected using Lipo-
fectAMINE Plus reagent per the manufacture’s proto-
col (Gibco BRL, MD). Cells were harvested 48–72 hr
after transfection.
Immunoblotting
Cells and postnatal mouse tissues were homogenized
in ice-cold extracting buffer containing 25 mM Tris-
HCl (pH 7.4), 250 mM sucrose, 5 mM EDTA, 2 mM
phenylmethylsulfonyl fluoride (PMSF) in the presence
of a 1% protease inhibitor cocktail [4-(2-aminoethyl)-
benzenesulfonyl fluoride, pepstatin A, transepoxysuc-
cinyl-L-leucylamido(4-guanidino)butane, bestatin, leu-
peptin, and aprotinin] (Sigma, St. Louis, MO).
Following a Bradford protein assay (BioRad Laborato-
ries) using BSA as standard, protein homogenates
were diluted in Laemmli sample buffer, separated by
SDS-PAGE (Laemmli 1970) and electrotransferred
onto Immobilon-P membranes (Millipore, MA) (Towbin
et al., 1979). Membranes were incubated in anti-Fgd1
antibody (1:5,000) or monoclonal anti-myc epitope an-
tibody (1:10,000; Invitrogen) overnight at 4°C. Immu-
noblots were incubated with secondary HRP-conju-
gated antibody (1:10,000; Pierce), and detected using
chemiluminescent reagents (ECL; Amersham).
Clinical Evaluation of Faciogenital Dysplasia
Patients
Informed consent was obtained from all participants
evaluated at the University of Michigan Medical Sys-
tem in accordance with the Human Subjects Research
Committee. Clinical evaluations were obtained without
prior knowledge of genotype status. Physical examina-
tion and radiographic studies were used to assess skel-
etal abnormalities. Several extensive patient clinical
evaluations have been reported previously (Gorlin et
al., 1990; Porteous and Goudie, 1991); detailed skeletal
findings of the other patients are our unpublished data.
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